Study on the Protective Efficacy of the Japanese Encephalitis Live Attenuated Vaccine SA14-14-2 Against Newly Isolated Genotype I Japanese Encephalitis Viruses
Shuai Shang, Qikai Yin, Tingyi Che, Xinzhu Wang, Qi Su, Shihong Fu, Hongshan Xu, Yongxin Yu, Qunying Mao, Huanyu Wang, Xinyu Liu · 2026
Read Study on the Protective Efficacy of the Japanese Encephalitis Live Attenuated Vaccine SA14-14-2 Against Newly Isolated Genotype I Japanese Encephalitis Viruses by Shuai Shang, Qikai Yin, Tingyi Che, Xinzhu Wang, Qi Su, Shihong Fu, Hongshan Xu, Yongxin Yu, Qunying Mao, Huanyu Wang, Xinyu Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13211682.txt.
Description
Shuai Shang and co-authors check whether a genotype III vaccine still blocks the genotype I encephalitis virus now dominant in Asia. Their 2026 study starts from a shift: genotype I has replaced genotype III across China and Southeast Asia this century. The live vaccine, licensed in 1988, has passed one billion doses in thirteen countries.
Fresh Chinese isolates are typed first. Challenge tests and antibody measures then compare protection across genotypes. Despite antigen gaps between the strains, protection after challenge shows no significant difference. Antibody levels back the same verdict. The authors conclude the old vaccine seed still guards against the new dominant genotype. Their systematic check settles a question hanging over a flagship immunization program.
Catalog record
| CREATOR | Shuai Shang, Qikai Yin, Tingyi Che, Xinzhu Wang, Qi Su, Shihong Fu, Hongshan Xu, Yongxin Yu, Qunying Mao, Huanyu Wang, Xinyu Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |